Skip to main content
Premium Trial:

Request an Annual Quote

Janssen to Use Adaptive's NGS Immune Profiling Assay to Study Drug Response

NEW YORK (GenomeWeb News) – Adaptive Biotechnologies said today that it has inked a biomarker discovery agreement with Janssen Research & Development.

Under the terms of the agreement, which was facilitated by the Johnson & Johnson Innovation Center, Adaptive will use its targeted next-gen sequencing-based ImmunoSeq assay to study immune response to diseases in order to identify patients more likely to respond to immunology and oncology drugs being developed by Janssen.

Adaptive provides fee-for-service access to its immune profiling sequencing technology in order to develop and validate potential clinical products. It also offers a laboratory-developed test, ClonoSeq, for monitoring minimal residual disease in blood-based cancers.